Lymphomatoid drug reaction developed after BNT162b2 (Comirnaty) COVID-19 vaccine manifesting as pityriasis lichenoides et varioliformis acuta-like eruption

J Eur Acad Dermatol Venereol. 2022 Mar;36(3):e172-e174. doi: 10.1111/jdv.17807. Epub 2021 Nov 24.

Authors

A Sernicola¹, A Dybala¹, V Gomes², P Maddalena¹, F Adotti³, G Soda³, R Muharremi¹, P Fino¹, E Del Duca¹, T Grieco¹

Affiliations

¹ Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, "Sapienza" University of Rome, Rome, Italy.
² Pathological Anatomy Unit, Ospedale San Filippo Neri, Rome, Italy.
³ Department of Radiological Sciences, Oncology and Anatomical Pathology, "Sapienza" University of Rome, Rome, Italy.

PMID: 34751995
DOI: 10.1111/jdv.17807

No abstract available

Publication types

Letter

MeSH terms

BNT162 Vaccine
COVID-19 Vaccines
COVID-19*
Humans
Pharmaceutical Preparations*
Pityriasis Lichenoides* / chemically induced
SARS-CoV-2

Substances

COVID-19 Vaccines
Pharmaceutical Preparations
BNT162 Vaccine